EGFR and neoplasm: Here, we evaluated the immune statuses of tumor tissues from EGFR‐mutant versus EGFR‐WT advanced NSCLC patients, as well as xenograft tumors through LLC lines transduced with the EGFR‐19del or EGFR‐WT gene and found that the EGFR mutations could fundamentally influence CD8+ T cells infiltration into tumor, which was consistent with previous studies.[40, 41] What we found was that the functional loss of DCs might be a crucial factor for impeding CD8+ T cells infiltration into EGFR mutated tumors.